Internal Medicine, Hematology & Oncology · Overland Park, KS
NPI
1396716056
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
10701 Nall Ave Ste 100
Overland Park, KS, 66211
Phone (913) 338-5585
Groups this clinician bills Medicare through
Medicare paid, 2024
$377K
9,017 services
Medicare patients, 2024
661
Average age 77
Drug cost, 2024
$41.8M
5,544 prescriptions
Company payments, 2025
$639
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sukumar Ethirajan was code J0897 (injection, denosumab, 1 mg), 4,800 times for 22 patients. In total Sukumar Ethirajan billed 9,017 services in 27 codes, and Medicare paid $377K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,800 | 22 | $19.88 | $95K |
| 99214 Office E&M - Established | Office | 1,174 | 568 | $90.37 | $106K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 884 | 187 | $140.80 | $124K |
| 96402 Chemotherapy Administration | Office | 280 | 187 | $24.77 | $6,935 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 208 | 175 | $11.79 | $2,451 |
| 36415 Venipuncture Blood Collection | Office | 188 | 161 | $8.65 | $1,626 |
| 99204 Office E&M - New | Office | 185 | 185 | $124.29 | $23K |
| 84153 Clinical Chemistry | Office | 175 | 148 | $18.02 | $3,154 |
| 85025 Blood Count | Office | 165 | 139 | $7.61 | $1,256 |
| 84403 Clinical Chemistry | Office | 165 | 142 | $25.29 | $4,173 |
| 80053 Clinical Chemistry | Office | 159 | 135 | $10.35 | $1,646 |
| 96372 Injection Administration | Office | 40 | 22 | $10.86 | $434 |
| 99213 Office E&M - Established | Office | 22 | 21 | $66.25 | $1,458 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 21 | 12 | $46.06 | $967 |
| 74176 CT/CTA - Abdomen and Pelvis | Office | 13 | 13 | $79.99 | $1,040 |
By year: 2022 $847K for 31,647 services; 2023 $606K for 17,579 services; 2024 $377K for 9,017 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 188 | 161 | $8.65 | $1,626 |
| 84153 Clinical Chemistry | 175 | 148 | $18.02 | $3,154 |
| 84403 Clinical Chemistry | 165 | 142 | $25.29 | $4,173 |
| 85025 Blood Count | 165 | 139 | $7.61 | $1,256 |
| 80053 Clinical Chemistry | 159 | 135 | $10.35 | $1,646 |
Medicare prescription drug claims, 2024
In 2024, the drug Sukumar Ethirajan prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 1,540 prescriptions and refills. In total Sukumar Ethirajan wrote 5,544 Medicare prescriptions that cost $41.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 1,540 | 1,544 | 229 | $21.5M |
| Nubeqa Darolutamide | 941 | 941 | 115 | $12.5M |
| Prednisone Generic | 937 | 974 | 136 | $7,304 |
| Abiraterone Acetate Generic | 923 | 952 | 127 | $1.5M |
| Orgovyx Relugolix | 710 | 710 | 130 | $1.9M |
| Erleada Apalutamide | 209 | 209 | 29 | $3.0M |
| Lynparza Olaparib | 50 | 50 | Under 11 | $820K |
| Alendronate Sodium Generic | 47 | 130 | 29 | $394 |
| Bicalutamide Generic | 33 | 42 | 32 | $558 |
| Methylprednisolone Generic | 22 | 22 | Under 11 | $477 |
| Yonsa Abiraterone Acet,submicronized | 19 | 19 | Under 11 | $188K |
| Talzenna Talazoparib Tosylate | 17 | 17 | Under 11 | $308K |
| Morphine Sulfate Er Morphine Sulfate | 12 | 12 | Under 11 | $338 |
Brand drugs: 3,499 claims; generic drugs: 2,045 claims; opioid claims: 31.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sukumar Ethirajan $639 ($639 in general payments such as food, travel and fees) from 8 companies. The largest payer was Novartis Pharmaceuticals Corporation with $388.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.